

# NEW YORK Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	19,546,700	19,576,900	19,540,200	19,477,400
Prediabetes	5,365,100	5,550,600	5,706,000	5,695,300
Diagnosed diabetes	1,537,400	1,823,800	2,046,600	2,202,800
Undiagnosed diabetes	568,200	640,200	681,600	695,100
Total with diabetes (diagnosed and undiagnosed)	2,105,600	2,464,000	2,728,200	2,897,800
<b>Complications:</b>				
Visual impairment	252,100	290,300	316,200	330,400
Renal failure	3,660	4,190	4,540	4,720
Leg amputations	3,180	3,470	3,580	3,550
Annual deaths attributable to diabetes	16,560	18,750	19,980	20,370
Total annual cost (2015 dollars)	\$24.7 B	\$28.7 B	\$31.8 B	\$33.8 B
Annual medical costs	\$17.7 B	\$20.4 B	\$22.5 B	\$23.9 B
Annual nonmedical costs	\$7.0 B	\$8.3 B	\$9.3 B	\$9.9 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	2,943,500	3,250,000	3,606,700	3,916,900
Prediabetes	1,501,200	1,657,500	1,839,400	1,997,600
Diagnosed diabetes	556,300	614,300	681,700	740,300
Undiagnosed diabetes	206,000	227,500	252,500	274,200
Total with diabetes (diagnosed and undiagnosed)	762,400	841,800	934,100	1,014,500
<b>Complications:</b>				
Visual impairment	104,100	111,900	121,100	128,100
Renal failure	1,710	1,830	1,960	2,060
Leg amputations	1,290	1,310	1,340	1,350
Annual deaths attributable to diabetes	11,420	12,560	12,990	12,830
Total annual cost (2015 dollars)	\$9.7 B	\$10.8 B	\$11.9 B	\$13.0 B
Annual medical costs	\$9.1 B	\$10.1 B	\$11.2 B	\$12.2 B
Annual nonmedical costs	\$0.6 B	\$0.7 B	\$0.7 B	\$0.8 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit [www.altfutures.org/diabetes2030](http://www.altfutures.org/diabetes2030).

Research funded by Novo Nordisk Inc.